Anti-AN13A/ ANKRD13A/ ANKRD13 monoclonal antibody
Anti-AN13A/ ANKRD13A/ ANKRD13 antibody for FACS & in-vivo assay
Go to ANKRD13A/ANKRD13A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-MP1990-Ab-1/ GM-Tg-hg-MP1990-Ab-2 | Anti-Human ANKRD13A monoclonal antibody | Human |
| GM-Tg-rg-MP1990-Ab-1/ GM-Tg-rg-MP1990-Ab-2 | Anti-Rat ANKRD13A monoclonal antibody | Rat |
| GM-Tg-mg-MP1990-Ab-1/ GM-Tg-mg-MP1990-Ab-2 | Anti-Mouse ANKRD13A monoclonal antibody | Mouse |
| GM-Tg-cynog-MP1990-Ab-1/ GM-Tg-cynog-MP1990-Ab-2 | Anti-Cynomolgus/ Rhesus macaque ANKRD13A monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-MP1990-Ab-1/ GM-Tg-felg-MP1990-Ab-2 | Anti-Feline ANKRD13A monoclonal antibody | Feline |
| GM-Tg-cang-MP1990-Ab-1/ GM-Tg-cang-MP1990-Ab-2 | Anti-Canine ANKRD13A monoclonal antibody | Canine |
| GM-Tg-bovg-MP1990-Ab-1/ GM-Tg-bovg-MP1990-Ab-2 | Anti-Bovine ANKRD13A monoclonal antibody | Bovine |
| GM-Tg-equg-MP1990-Ab-1/ GM-Tg-equg-MP1990-Ab-2 | Anti-Equine ANKRD13A monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-MP1990-Ab-1/ GM-Tg-hg-MP1990-Ab-2; GM-Tg-rg-MP1990-Ab-1/ GM-Tg-rg-MP1990-Ab-2; GM-Tg-mg-MP1990-Ab-1/ GM-Tg-mg-MP1990-Ab-2; GM-Tg-cynog-MP1990-Ab-1/ GM-Tg-cynog-MP1990-Ab-2; GM-Tg-felg-MP1990-Ab-1/ GM-Tg-felg-MP1990-Ab-2; GM-Tg-cang-MP1990-Ab-1/ GM-Tg-cang-MP1990-Ab-2; GM-Tg-bovg-MP1990-Ab-1/ GM-Tg-bovg-MP1990-Ab-2; GM-Tg-equg-MP1990-Ab-1/ GM-Tg-equg-MP1990-Ab-2 |
| Products Name | Anti-ANKRD13A monoclonal antibody |
| Format | mab |
| Target Name | ANKRD13A |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-ANKRD13A benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species AN13A/ ANKRD13A/ ANKRD13 VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | pGMLPm004052 | mouse Ankrd13a Lentivirus plasmid |
| ORF Viral Vector | vGMLPm004052 | mouse Ankrd13a Lentivirus particle |
Target information
| Target ID | GM-MP1990 |
| Target Name | ANKRD13A |
| Gene ID | 88455,68420,360823,708383,609384,101084139,511883,100066442 |
| Gene Symbol and Synonyms | 1100001D10Rik,ANKRD13,ANKRD13A,NY-REN-25 |
| Uniprot Accession | Q8IZ07 |
| Uniprot Entry Name | AN13A_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000076513 |
| Target Classification | N/A |
The target: ANKRD13A, gene name: ANKRD13A, also named as ANKRD13, NY-REN-25. Enables ubiquitin-dependent protein binding activity. Involved in negative regulation of protein localization to endosome and negative regulation of receptor internalization. Located in late endosome; perinuclear region of cytoplasm; and plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab


GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.

